Over the trailing 12 months, BDTX insiders made no open-market trades in the stock.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Venture Capital Vi, L.P. Versant | TenPercentOwner | 3,726,341 | 0 | 3,726,341 | 33.1% | 30 Aug, 2024 |
| 2 | Capital Management, L.P. Ra | Director | 0 | 3,213,828 | 3,213,828 | 28.5% | 07 Jul, 2023 |
| 3 | Growth N V Biotech | TenPercentOwner | 2,733,547 | 0 | 2,733,547 | 24.3% | 20 Mar, 2025 |
| 4 | David M. Epstein | Director, Officer | 671,423 | 0 | 671,423 | 6.0% | 28 Jun, 2023 |
| 5 | Elizabeth Buck | Chief Scientific Officer | 170,192 | 0 | 170,192 | 1.5% | 31 Jan, 2025 |
| 6 | Fang Ni | Officer | 125,389 | 0 | 125,389 | 1.1% | 23 Dec, 2022 |
| 7 | Mark A. Velleca | President Ceo | 121,522 | 0 | 121,522 | 1.1% | 31 Jan, 2025 |
| 8 | Ali Behbahani | Director | 110,236 | 0 | 110,236 | 1.0% | 21 Sep, 2026 |
| 9 | Erika Jones | Officer | 85,150 | 0 | 85,150 | 0.8% | 31 Jan, 2025 |
| 10 | Brent Hatzis-Schoch | Officer | 83,400 | 0 | 83,400 | 0.7% | 31 Jan, 2025 |
| 11 | Sergey Yurasov | Chief Medical Officer | 75,000 | 0 | 75,000 | 0.7% | 31 Jan, 2025 |
| 12 | Prakash Raman | Director | 51,840 | 0 | 51,840 | 0.5% | 21 Sep, 2026 |
| 13 | Robert Alexander Ingram | Other | 42,854 | 0 | 42,854 | 0.4% | 19 Dec, 2022 |
| 14 | Wendy L Dixon | Director | 38,054 | 0 | 38,054 | 0.3% | 03 Apr, 2024 |
| 15 | Shannon Campbell | Director | 8,865 | 0 | 8,865 | 0.1% | 16 Dec, 2024 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 18 Sep, 2026 | Ali Behbahani | Director | Acquired A | 7,707 | $1.93 | $14.87K | 110,236 | Direct |
| 18 Sep, 2026 | Prakash Raman | Director | Acquired A | 6,801 | $1.93 | $13.13K | 51,840 | Direct |
| 26 Jun, 2026 | Prakash Raman | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 26 Jun, 2026 | Kapil Dhingra | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 26 Jun, 2026 | Garry E Menzel | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 26 Jun, 2026 | Ali Behbahani | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 26 Jun, 2026 | Samarth Kulkarni | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 26 Jun, 2026 | Shannon Campbell | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 19 Jun, 2026 | Prakash Raman | Director | Acquired A | 7,907 | $1.66 | $13.13K | 45,039 | Direct |
| 19 Jun, 2026 | Ali Behbahani | Director | Acquired A | 8,961 | $1.66 | $14.88K | 102,529 | Direct |
| 20 Mar, 2026 | Ali Behbahani | Director | Acquired A | 6,919 | $2.15 | $14.88K | 93,568 | Direct |
| 20 Mar, 2026 | Prakash Raman | Director | Acquired A | 6,105 | $2.15 | $13.13K | 37,132 | Direct |
| 21 Jan, 2026 | Mark A. Velleca | President Ceo | Acquired A | 600,000 | $0.00 | $0 | 600,000 | Direct |
| 21 Jan, 2026 | Elizabeth Buck | Chief Scientific Officer | Acquired A | 250,000 | $0.00 | $0 | 250,000 | Direct |
| 21 Jan, 2026 | Sergey Yurasov | Chief Medical Officer | Acquired A | 250,000 | $0.00 | $0 | 250,000 | Direct |
| 21 Jan, 2026 | Brent Hatzis-Schoch | Officer | Acquired A | 250,000 | $0.00 | $0 | 250,000 | Direct |
| 21 Jan, 2026 | Erika Jones | Officer | Acquired A | 200,000 | $0.00 | $0 | 200,000 | Direct |
| 12 Dec, 2025 | Prakash Raman | Director | Acquired A | 4,665 | $2.76 | $12.88K | 31,027 | Direct |
| 12 Dec, 2025 | Ali Behbahani | Director | Acquired A | 5,208 | $2.76 | $14.37K | 86,649 | Direct |
| 19 Sep, 2025 | Ali Behbahani | Director | Acquired A | 4,291 | $3.35 | $14.37K | 81,441 | Direct |